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The Statistical Methods Group has played a pivotal role in The Cochrane Collaboration over the past 20 years. The
Statistical Methods Group has determined the direction of statistical methods used within Cochrane reviews,
developed guidance for these methods, provided training, and continued to discuss and consider new and
controversial issues in meta-analysis. The contribution of Statistical Methods Group members to the meta-analysis
literature has been extensive and has helped to shape the wider meta-analysis landscape.
In this paper, marking the 20th anniversary of The Cochrane Collaboration, we reflect on the history of the Statistical
Methods Group, beginning in 1993 with the identification of aspects of statistical synthesis for which consensus
was lacking about the best approach. We highlight some landmark methodological developments that Statistical
Methods Group members have contributed to in the field of meta-analysis. We discuss how the Group implements
and disseminates statistical methods within The Cochrane Collaboration. Finally, we consider the importance of
robust statistical methodology for Cochrane systematic reviews, note research gaps, and reflect on the challenges
that the Statistical Methods Group faces in its future direction.Background
Although there are earlier examples of statistical combin-
ation of data from multiple studies, the practice began in
earnest in the 1970s in the social sciences, and the term
meta-analysis was coined by Glass as recently as 1976 [1].
Systematic reviews, including statistical synthesis of the re-
sults of multiple studies, are now commonplace in medical
research, notably through the work of The Cochrane Col-
laboration. Yet it is only about 30 years since these studies
began to appear in medical journals.
Methodological rigour was a key principle of The
Cochrane Collaboration from its inception two decades
ago. Accordingly, statistical methods have always been
seen as critically important. In this article, we provide a
historical account of the beginnings of the Statistical
Methods Group (SMG) of The Cochrane Collaboration
and its subsequent work, and reflect on the challenges
that the group faces in the future. Many individuals and
organisations outside the Collaboration have made* Correspondence: joanne.mckenzie@monash.edu
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reproduction in any medium, provided the orsignificant contributions to the development of statistical
aspects of systematic review methods in health care;
however, in this paper, we restrict our focus to contribu-
tions of the SMG and its members.History of the Statistical Methods Group
A key publication pre-dating the founding of The
Cochrane Collaboration was the two volume Effective
Care in Pregnancy and Childbirth, which included a long
chapter on methods for synthesising evidence from mul-
tiple studies (now called systematic reviews), including
methods of meta-analysis [2]. It was recognised, however,
that the field was in its infancy and there were many unre-
solved issues. Accordingly, the first Cochrane meeting on
statistics was held at the UK Cochrane Centre in Oxford
in July 1993, masterminded by Iain Chalmers and co-
chaired by Ken Schulz and Doug Altman. This meeting
took place just one week after a one-day meeting in
London on ‘Systematic Reviews’, organised jointly by the
British Medical Journal and the UK Cochrane Centre,
which led to a book of the same name [3].ral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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months) the creation of The Cochrane Collaboration,
the goal of reviewing the literature on healthcare inter-
ventions across specialties was already clear. There were
16 participants, most of whom were statisticians. The
workshop was convened to develop guidelines on statis-
tical methods for data synthesis. The hope was that the
meeting would identify areas where there was reasonable
consensus, and those which caused debate and could be
the subject of further research. Opening the meeting,
Andy Oxman described the need to develop guidelines
for people preparing systematic reviews. His suggestion
that it was desirable for the statistical methods to be
consistent across reviews as far as possible was en-
dorsed by most participants. It was agreed that the
planned Cochrane Collaboration software should have
explicit default methods of analysis and presentation
but that reviewers be able to override these. Areas
where there was much discussion but a lack of consen-
sus included the use of odds ratio or relative risk (risk
ratio) for meta-analysis of binary outcomes and the use
of fixed or random effects analyses in the presence of
heterogeneity. The minutes and list participants from
this meeting are available in Additional file 1 - Oxford
1993 Workshop Report.
Following on from the meeting, Doug Altman and
Ken Schulz became the founding co-convenors of the
Statistical Methods Working Group (SMWG), as it was
initially called. (The term ‘working’ was later dropped
from the names of all Cochrane Methods Groups.) The
SMWG produced an initial list of ‘possible research
topics’, shown in Table 1. They noted that “This list indi-
cates some areas where either there is no consensus as
yet about the best approach or where inadequate infor-
mation is available. It should not be taken as an inclusive
list of all intended topics of investigation.” From the
1993 recommendations onwards, the SMG has had a
major influence on the specification of The Cochrane
Collaboration software, especially in relation to meta-
analysis, as discussed below.
The participants at the 1993 meeting also noted the
importance of studying the benefits of collecting individual
patient data versus using published summary statistics. That
topic was deemed to fit more within the remit of a specialist
group, and a meeting of interested parties in Oxford in
April 1994 led to the founding of the Meta-analyses using
Individual Patient Data Methods Working Group [4].
In March 1995, an application was made for the
“Cochrane Collaboration Working Group on Statistical
Methods for Data Synthesis” to be formally registered. At
that time the group put forward the following objectives:
 To develop and update guidelines on statistical
methods for data synthesis. To develop and update guidelines for the integration
of the methodological quality of randomised
controlled trials into statistical methods for data
synthesis.
 To serve as a “clearinghouse” for names of
individuals who are willing and able to provide
technical consultations to those in The Cochrane
Collaboration on specific methodological issues.
It was recognised early that the SMG would benefit
from funding to support methodological explorations
and development of enhanced guidance, and the SMG
made the following argument in an unsuccessful attempt
to get funding in 1997:
“Many of the statistical queries and issues in the
Cochrane Collaboration are not straightforward.
While the basic statistical methods for meta-analysis
are well known, in any particular systematic review it
is unusual for these to be applicable without prob-
lems. For example there are often difficulties in
extracting the required information from publications,
in addressing both clinical and statistical heterogeneity
between trials, in considering the potential effects of
publication bias, in undertaking appropriate sensitivity
analyses to investigate the robustness the conclusions
made, and in investigating the effects of methodo-
logical quality of the primary studies on the overall re-
sults and interpretation. These difficult issues require
both empirical and methodological work.”
In the absence of dedicated funding for the SMG,
however, methodological advances by members of the
group have been motivated by SMG discussions (and
other Cochrane activities) but not determined by the
SMG. Thus, progress addressing these research topics
has been piecemeal. Yet members of the group have
made many key contributions to advancing the statistical
aspects of systematic review methods, as well as author-
ing several books on methods for systematic reviews and
meta-analyses (for example, [5-9]). Thus evolution of stat-
istical methodology used in Cochrane reviews was in-
formed mainly through discussion of new developments
initiated outside the Collaboration, although many SMG
members were involved in those advances. In 1997, the
SMG merged with the Quality of Reporting Trials
Methods Group, led by David Moher, who became a co-
convenor of the SMG.
Communication within SMG was always primarily via
an email discussion list. Membership of the SMG grew
(from 33 members in 1995, to 133 by 2006), with the
group acting primarily as a discussion forum. To try to
advance understanding of specific methodological areas
in the late 1990s, the SMG established subgroups for
Table 1 Research topics proposed in 1995 for the Cochrane Statistical Methods Working Group
Topic Comments
Continuous outcome measures More work is needed on methods for combining results from trials with continuous
outcome measures, especially with regard to the choice of effect measure, distribution of
the data, baseline assessments and missing data. Of particular interest, perhaps, is the issue
of combining results from trials where continuous outcome data have been categorised
using varying cut-points and number of groups, or where some trials have presented results
grouped and others as continuous.
Combining parallel group and cross-over trials Work is needed to evaluate strategies for combining information from parallel group and
cross-over trials, and to consider the information that needs to be supplied in reports of
cross-over trials to enable them to be used in this way.
Heterogeneity Given the lack of consensus at the workshop, it would be valuable to gain more insight into
the merits of various strategies for combining trials when statistical heterogeneity is found.
More empirical research into the effects of variation in methodology on heterogeneity
would be valuable
Combining trials with different endpoints It would be useful to consider what, if anything, can be done to combine trials that use
different endpoints (This is a generalisation of the issue of combining data from trials where
the same endpoint is assessed in different ways).
Summary statistics More work is needed examining the relative merits of odds ratios, relative risks, NNTs and so
on for meta-analysis of RCTs.
Extraction of summary statistics from published trials
where the endpoint is survival time
Methods to combine results from survival studies where individual data are not available
need to be investigated. Guidelines for minimum standards for reporting such trials should
be developed.
Ignoring survival times A study could be carried out of the loss of information (and power?) arising from classifying
patients by presence or absence of the event of interest rather than by time to event. The
effect of the varying length of follow-up should be examined.
Presentation of meta-analyses - numerical Studies should be encouraged examining the merits of odds ratios, relative risks, NNT and
other approaches for producing numerical summaries of the results of meta-analyses.
Presentation of meta-analyses - graphical Various aspects of graphical presentation vary among published meta-analyses. The relative
merits of these should be systematically reviewed. If possible, recommendations should be
developed for standard graphical presentation. Aspects to consider include ordering of trials,
symbols used, whether or not log scale used for treatment effect, and whether any add-
itional graphs might usefully supplement the standard type.
Random effects models It would be useful to have clarification of the properties of the various strategies for fitting
random effects models.
Combining results from observational studies Methods for combining results from observational studies, such as case-control studies, need
to be investigated. In particular, methods are needed to pool estimated regression
coefficients.
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join these. The most overt success came from a group of
SMG members who were interested in the incorporation
of crossover trials in meta-analyses. Their work led to a
journal publication [10].
Statistical issues relating to systematic review of diag-
nostic test accuracy were never part of the SMG’s remit,
as the Screening and Diagnostic Tests Methods Group
had also existed from the early years of the Collabor-
ation. However, other parts of the SMG’s scope have
split off into specialist Methods Groups over time. In
2000, the activities relating to problems of reporting re-
search were taken up by a newly formed Reporting Bias
Methods group (renamed the Bias Methods Group in
2005). Statistical methods for other specific contexts
have also been addressed by the formation of other new
methods groups, notably the Non-randomised Studies
Methods Group in 1999 and Comparing Multiple Inter-
ventions Methods Group in 2010.The Statistical Methods Group and
methodological developments in meta-analysis
The SMG has maintained and promoted a research
agenda of issues important to the statistical synthesis of
study findings. Important methodological developments
have often been motivated through SMG members’ in-
volvement in Cochrane reviews and through discussion
on the SMG email list, at training events and during
scientific meetings (see next section for more detail).
Most of the research topics that were identified by
the Group in 1995 (Table 1) have now been addressed,
and the guidance based on this research is offered
in the Cochrane Handbook for Systematic Reviews of
Interventions (henceforth referred to as the Cochrane
Handbook) [8]. The Cochrane Handbook has had sub-
stantial impact, with more than 7,000 citations, ap-
proximately 74% of which are from sources other than
Cochrane Reviews [11]. While not all these citations
can be attributed to the statistical chapters 9, 10 and 16
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Handbook, and are a key resource for statistical synthe-
sis in systematic reviews.
The contribution of SMG members to the meta-analysis
literature and the Cochrane Handbook has been extensive
and has helped to shape the wider meta-analysis landscape.
These contributions have included not only methodological
developments, but also empirical studies that have evaluated
existing methods. Below we highlight some landmark
methodological developments that have influenced the
field of meta-analysis. We include highly cited papers, and
those that have received awards at Cochrane Colloquia
(the annual conferences of The Cochrane Collaboration),
made an important novel contribution, or generated
important debate. This list is not exhaustive or fully
representative of the research activity of SMG members.
A full list of publications and current SMG members
can be found online at smg.cochrane.org/publications
and smg.cochrane.org/our-contributors.
The importance of the choice of the effect measure for
dichotomous data in the presence of heterogeneity was
examined by Deeks [15]. Results from this research have
largely framed current guidance that suggests relative
measures (odds ratio or risk ratio) to be preferable to ab-
solute (risk difference) (for example, [9,12,16]). Sweeting
et al. [17], Bradburn et al. [18] and others have evalu-
ated the methodology for sparse dichotomous data and
made suggestions for their optimal modelling [19,20].
The potential of the ratio of means for continuous out-
comes as an alternative effect measure to the mean dif-
ference and standardised mean difference was presented
at the 15th and 16th Cochrane Colloquia (in 2007 and
2008). A series of papers examining the performance of
this measure have been published [21-23]. Different
methods for meta-analysis of skewed data have been
evaluated [24]. Missing outcome data in trials with dichot-
omous outcomes have been addressed in meta-analyses
primarily through sensitivity analysis methods [25,26].
However, there are still many unanswered questions of
how best to handle missing outcome data in meta-analysis
of trials, particularly where the outcome is continuous,
and this led The Cochrane Collaboration to fund a project
on missing data in 2011. Methods for handling missing
standard deviations in meta-analysis have been described
and appraised in Wiebe et al. [27] and empirically evalu-
ated [28]. Clinical fields where survival data are common
have largely benefited from the development of methods
to combine time-to-event data [29-31].
SMG members have made methodological contributions
to the synthesis of results from trials with non-standard
designs. Extensive research has been undertaken evaluating
strategies for combining results from parallel group
and cross-over trials [10,32-34], and simple methods
to deal with paired data (such as eyes or arms) havebeen proposed [35]. These methods are recommended
in the Cochrane Handbook.
The I2 statistic, which quantifies the amount of hetero-
geneity [36], is now probably the most popular method
to evaluate heterogeneity (for example, [16,37,38]). The
general medical journal article published in 2003 that
describes I2 has been cited more than 6,000 times [39],
and the statistic has been included in RevMan (The
Cochrane Collaboration’s software to prepare and main-
tain reviews [40]). Problems with interpretation of the I2
statistic have been discussed [41]. Current guidance en-
courages reviewers to explore sources of heterogeneity
by employing techniques such as subgroup analysis and
meta-regression, although the pitfalls of such post-hoc
analyses have been highlighted [42]. While meta-regression
has not been implemented in RevMan, since this method is
rarely appropriate in Cochrane reviews which typically
include few studies [43], results and graphs from meta-
regression fitted in statistical packages can be easily
imported into RevMan. A significance test to investigate if
there are differences between two or more subgroups has
recently been added [9]. Cochrane Handbook guidance
recommends the use of random effects in the presence of
unexplained heterogeneity and the results are summarised
in terms of an average combined effect size and its stand-
ard error. However, more recently, it has been proposed
that in the presence of unexplained heterogeneity, an
average effect is not informative, and that instead, the dis-
tribution of effects should be considered [44]. This has led
to the development of different methods to calculate pre-
diction intervals, which better convey heterogeneity of the
results [44].
One particular source of heterogeneity that has been
observed in meta-analyses is the difference in the mag-
nitude of effects between small and large studies, often
termed ‘small-study effects’. The Cochrane Handbook
explicitly warns against misinterpreting funnel plot
asymmetry as necessarily indicating publication bias,
and the connections between heterogeneity, funnel plot
asymmetry and small study effects have long been a
focus of members of the SMG [45]. Consequently,
SMG members have published several methodological
developments evaluating the possibility of small study
effects [46-52], visualizing them [53] and accounting
for them [54-58].
SMG members have undertaken methodological work
on network meta-analysis (also called multiple-treatments
meta-analysis and mixed-treatment comparison), a multi-
dimensional extension of meta-analysis aiming to make
inferences about the relative effectiveness of many treat-
ments for the same health condition. The methodology,
presented in Higgins and Whitehead [59], takes advantage
of indirect evidence in a network of interventions and has
attracted much interest in recent years within the SMG
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shops and contributing talks on the topic have been pre-
sented at Cochrane Colloquia since 2005. SMG members
have contributed many methodological and applied publi-
cations on this topic in the scientific literature (see, for ex-
ample, [60-69]).
The SMG recognised early on the potential of the
method to answer policy-relevant questions and, because
of the specialist nature of the methods, initiated the cre-
ation of the Comparing Multiple Interventions Methods
Group (CMIMG). The role of the CMIMG is to develop
and maintain guidance for undertaking and publishing
Cochrane Reviews that compare multiple interventions
via network meta-analysis. The promise of network
meta-analysis has led to rapid development and adop-
tion of the methods, stimulating collaboration between
members of the CMIMG and researchers external to
The Cochrane Collaboration.
Many of the SMG developments outlined above were
initially presented at Cochrane Colloquia, and several
have received the Thomas C Chalmers award, an award
presented for best oral or poster presentation at a
Cochrane Colloquium addressing methodological issues
related to systematic reviews. SMG members have re-
ceived in total 11 prizes on topics strictly within the
scope of the SMG (Table 2), and several more for pre-
sentations that relate to bias, individual participant data
and diagnostic tests.
SMG members have also co-authored publications that
fall under the remit of other Cochrane methods groups
including the Individual Participant Data Meta-analysis
Methods Group (ipdmamg.cochrane.org), Prospective Meta-Table 2 Thomas C Chalmers awards for statistical issues relat
Year Authors Title
1996 Liberati A, D’Amico R, Torri V, Tinazzi A, Leonetti C,
Pifferi S
Meta-analyses
1998 Deeks J, Bradburn M, Bilker W, Localio R, Berlin J Much ado abo
1999 Higgins J How should w
2001 Deeks JJ Half dead or h
ratios?
2003 Hollis S and Preston C Allowing for u
best/worst cas
2005 Brok J, Thorlund K, Wetterslev J, Gluud C Trial sequentia
adequacy of a
Salanti G, Higgins J, Marinho V How to determ
(MTM) of trials
2006 Skipka G The inclusion o
meta-analyses
2007 Friedrich J, Adhikari N, Ohlsson A, Beyene J Ratio of means
variables in a m
Patsopoulos N, Ioannidis J, Evangelou E Uncertainty of
2008 Anzures-Cabrera J, Higgins JPT Expressing meAnalysis Methods Group (pma.cochrane.org), Bias Methods
Group (bmg.cochrane.org), Prognosis Methods Group
(prognosismethods.cochrane.org) and the Non-Randomised
Studies Methods Group.
Implementation and dissemination of statistical
methods within The Cochrane Collaboration
The SMG is involved in a range of activities within the
Collaboration that aim to provide support to systematic
review authors, the staff of Cochrane Review Groups
and statisticians. A particular role of the SMG is to pro-
vide guidance when there are alternative approaches,
such as handling multi-arm trials, handling missing out-
comes within trials, imputing standard deviations when
not presented, and mixing means with medians.
All CRGs are expected to involve statisticians [70]. They
contribute to the CRGs in various ways including being
statistical editors of CRGs; peer review, collaboration and
authorship on systematic reviews; development of methods
resources for CRGs; involvement in methodological quality
improvement; and responding to statistical queries. In
addition, statisticians in some CRGs have undertaken re-
search to address methods issues prompted by their CRG
(for example, [71-74]). The SMG maintains an email list
that provides a forum for discussion of statistical issues
relevant to systematic reviews. Membership of the list con-
stitutes membership of the SMG, and includes CRG statis-
ticians and other statisticians/methodologists with an
interest in systematic review methods. The list currently
has 237 members (April 2013), from 27 countries, primar-
ily based in the UK (37%), USA (12%), Australia (10%),
Germany (9%) and Canada (8%).ed to systematic reviews
from different sources of information
ut nothing: statistical methods for meta-analysis with rare events
e interpret updated meta-analyses?
alf alive? Which way should events be coded for meta-analyses of risk
ncertainty due to missing data in a binary meta-analysis. Better than
e analysis?
l analyses of six Cochrane neonatal group meta-analyses considering
llocation concealment
ine the best treatment: a mixed-treatment-comparisons meta-analysis
of topical fluoride therapies for the prevention of dental caries
f the estimated inter-study variation into forest plots for random-effects
- a suggestion for a graphical presentation
as an alternative to mean differences for analyzing continuous outcome
eta-analysis: a simulation study
heterogeneity in meta-analysis
ta-analyses of continuous outcomes in terms of risks
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of statistical methods through training at regional
Cochrane events and Colloquia, reviewing of standard
review author training materials, and contributions to
the Cochrane Handbook [8]. A set of core workshops,
targeting review authors and CRG staff, are presented at
Colloquia covering introductory topics on meta-analysis
including: basic ideas, meta-analysis of binary and con-
tinuous outcomes, dealing with heterogeneity, and inclu-
sion of non-standard studies and non-standard data. A
full list of workshops presented at Colloquia is available
at smg.cochrane.org/teachingtraining-workshops. The
SMG has run two major training events for Cochrane
statisticians. The first ‘Summer school for Cochrane
Statisticians’ was held in Oxford, UK, in July 2001, while
the second, ‘Cochrane Statistical Methods Group Training
Course: Addressing advanced issues in meta-analytical
technique’ was held in Cardiff, UK, in April 2010. The latter
course led to a series of freely available online materials,
including slidecasts of the presentations (smg.cochrane.org/
teachingtraining-workshops/smg_training_course_2010).
In addition to training workshops, SMG members have
organised and presented in SMG scientific meetings,
special methods sessions, and plenaries at Cochrane
Colloquia. The purpose of these sessions has often been
to discuss or present new or controversial issues in
meta-analysis. Ad hoc meetings outside Cochrane
Colloquia have also been convened to discuss specific
methodological issues. Examples of key events are
presented in Table 3.
Discussion
What has statistics done for The Cochrane Collaboration?
The need for statistical synthesis methods to enable inter-
pretation of results from multiple studies was recognised
more than 50 years ago [1,75-77]. Meta-analyses now form
a core component of many Cochrane Reviews. Without
such a method, interpreting the effectiveness of an inter-
vention is difficult, if not impossible. Further, meta-
analysis allows the combining of results from a series of
small studies, to answer a question regarding the effective-
ness of an intervention, which could otherwise not be
answered from the individual studies. Extensions of meta-
analysis methods provide systematic review authors with
an extensive tool kit to answer questions beyond whether
an intervention is effective. For example, which factors
may modify the magnitude of the intervention effect
[42], what is the likely effect of an intervention in an
individual setting [44], or what is the relative effect-
iveness of many interventions for the same health
condition [64]. These extensions increase the utility
of systematic reviews in answering key questions of
relevance to policy makers, health care decision makers
and patients.What has The Cochrane Collaboration done for statistics?
The Cochrane Collaboration has provided the impetus,
structure and coordination for an international group of
methodologists to contribute to the development of statis-
tical aspects of systematic review methods. This has expe-
dited development of systematic review methods that
would not likely have been achieved as rapidly without
such an organisation. Coupled with the benefits of an
international collaboration of methodologists, the main
output of The Cochrane Collaboration, the Cochrane
Database of Systematic Reviews, has facilitated methodo-
logical research, by providing a large and unique reposi-
tory of data on systematic reviews and meta-analyses (for
example, [23,43,78-83]). A recent paper highlighted those
articles published in statistical journals that appear to be
having the most direct impact on general and internal
medicine research [84]. The authors identified the 18
most-cited biostatistical articles; 11 were about methodo-
logical aspects of meta-analysis, 7 of which were co-
authored by SMG members [17,18,32,36,42,48,64].
What are the research gaps in meta-analysis methods?
Further research to establish the optimal strategy for com-
bining intervention effects estimated from analyses of final
values and change scores is required [85]; SMG members
are currently investigating this area [86]. Further research
is also needed to develop and evaluate methods for com-
bining results from trials where continuous outcome data
have been categorised using varying cut-points [87]. A
related issue is the best approach to deal with the scenario
where trials present results for the same outcome based
on a mixture of continuous and dichotomous measures.
Statistical methods that adjust for potential bias in in-
cluded studies (as, for example, in Turner et al. [57])
might be desirable, particularly when non-randomised
studies are included. Evaluation of methods to adjust for
‘hidden’ clustering in individually randomised trials arising
through the organisation of the intervention (for example,
therapists treating groups of patients, or group therapy
sessions, surgical procedures) would be useful [88,89].
Development of methodology for meta-analysis of time-
to-event data that allow for more complex multistate
modeling, such as competing risks, is needed. Several de-
velopments have taken place in recent years in the field of
multivariate meta-analysis [90-92]. The potential of differ-
ent methods (for example, maximum likelihood, method
of moments and Bayesian approaches) to estimate param-
eters of multivariate meta-analysis models and the estima-
tion of within-study correlation in the absence of detailed
study-level data needs further attention [93,94]. Methods
to describe and quantify heterogeneity (for example, ex-
tending the I2 statistic) and visually display results from
multivariate meta-analysis have been recently suggested
[95] and their usefulness and performance remains to be
Table 3 Description of the Statistical Methods Group scientific meetings, special methods sessions, and plenaries
Year Event Description of event
1993 Oxford Colloquium Statistical Methods Working Group (later SMG) scientific meeting. Discussed the range of statistical
methods that The Cochrane Collaboration could use in undertaking meta-analyses and noted a lack
of consensus in appropriate methods.
1996 Oxford 1st Ad hoc meeting. Discussed an eclectic set of issues relating to the development of the MetaView
software (later developed into RevMan) and various methodological issues.
1996 Oxford 2nd Ad hoc meeting. Convened to discuss issues relevant to the analysis of ordinal data.
1998 Oxford 3rd Ad hoc meeting. Discussed issues related to cluster randomised trials in systematic reviews.
2001 Lyon Colloquium SMG scientific meeting. Discussion on fixed versus random effects meta-analysis and intention-to-treat
analysis. Consensus decision made regarding heterogeneity: that a test for heterogeneity should not
be used to decide between fixed and random effects models.
2002 Oxford Colloquium SMG scientific meeting: Several methodological issues discussed: cross-over trials, combining studies
with different designs and methods for dealing with heterogeneity.
2004 Edinburgh 4th Ad hoc meeting. Discussed issues relating to the quality assessment of trials.
2006 Melbourne Colloquium Special methods session: “Assessing susceptibility to bias of included studies: new recommendations
for Cochrane reviews”. First open meeting to introduce and discuss the proposed Risk of Bias tool
(as was later named).
2008 Freiburg Colloquium Satellite event to the Freiburg Colloquium: Joint meeting of the SMG and the UK Meta-analysis in
Medicine Group. Four sessions on: meta-analysis of continuous data, various topics, addressing risk
of bias, and a debate “When should meta-analyses be performed in Cochrane reviews?”
Special methods session “Some awkward statistical issues in Cochrane reviews”. Two topics
“Subsets of studies in meta-analysis” and “Meta-analysis with multiple treatment groups”.
2009 Singapore Colloquium Special methods session. Two parts: Part 1 “Exploring new approaches for dealing with bias and
heterogeneity” and Part 2 “RevMan and beyond for meta-analysis”.
Joint scientific meeting of the SMG and the Bias Methods Group. Three presentations on the assessment
and impact of outcome reporting bias on systematic reviews, searching for methods studies, and a
decision tool for updating Cochrane reviews.
2011 Madrid Colloquium SMG scientific meeting. Two topics, multivariate meta-analysis and trial sequential analysis, were presented
and discussed.
2012 Auckland Colloquium Methods plenary. Theme of plenary was “Beyond healthcare decisions: systematic reviews as a tool for
informing future research and research methodology”.
2013 Québec Colloquium Satellite event to the Québec City Colloquium: “Data, Outcomes, Uncertainty and Graphs: Advances and
Limitations in Trials, Meta-Analysis, and Novelties”. Four sessions on: selective reporting, bias, statistical
issues, and presentations considering the case for and against inclusion of funding source as a standard
item in the Cochrane Risk of Bias tool.
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tical methods used in Cochrane Reviews requires regular
assessment, particularly as new methods appear in the lit-
erature. Cochrane reviews have specific characteristics (for
example, they typically have few studies [43]) and know-
ledge of how synthesis methods perform, in which cir-
cumstances their performance is most compromised, and
how large the impact is when this occurs, is required to
develop guidance for the Cochrane Handbook, and include
the most appropriate methods in RevMan. Simulation
studies and extensive meta-epidemiological studies pro-
vide the necessary research to underpin this guidance.
Thoughts on our future direction
While 10 years ago, say, some may have felt that all the
main statistical issues in systematic reviews had been
addressed, the reality is that new challenges have contin-
ued to arise, and the pace of methodological work has
not slowed. While we cannot say in which areas futureinnovations will appear we are confident that such inno-
vations will indeed be made. And we expect the SMG
members to continue to be among those at the forefront
of this work. The SMG will continue to have a key role
in advising The Cochrane Collaboration on which
methods are, or are not, recommended, or whether new
approaches need more evaluation before a decision can
be made. They also have an important role in further re-
finement and extension of the handbook and other
training materials.
Despite the contribution SMG members have made to
advance the statistical aspects of systematic review
methods, funding the work of the SMG and, more
broadly, methodological research in evidence synthesis
remains an ongoing challenge. Methodological research
funding programmes, such as those provided in the
United Kingdom (for example, the Medical Research
Council/National Institute for Health Research Methodology
Research Programme), United States (for example, Agency
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comparative effectiveness), and Europe (for example, the
European Commission’s Seventh Framework Programme
and Horizon 2020), are critical for the ongoing development
and evaluation of methods, and production of guidance.
Specific funding for the SMG would allow for a more
priority-driven and structured approach to addressing
important gaps in statistical synthesis methods that are of
particular relevance to Cochrane Reviews, thus expediting
the availability of research on which to base well-informed
decisions. Incorporation into the Cochrane Handbook and
RevMan of new statistical synthesis methods that make the
best use of evidence will contribute to The Cochrane
Collaboration’s goal of producing high quality research
evidence. Given the impact of the Cochrane Handbook
and the widespread use of RevMan, the benefits would
likely extend well beyond reviews completed under the
auspices of The Cochrane Collaboration.
Conclusions
Over the past 20 years, the SMG has played a pivotal role
within The Cochrane Collaboration in determining
the direction of statistical methods used within Cochrane
reviews. Members of the SMG have made key contributions
to advancing statistical aspects of systematic reviews. Many
research gaps in statistical methods of systematic reviews
remain, and will continue to arise as the field of meta-
analysis develops. Statisticians and methodologists will lead
the development and evaluation of these methods, thus
being critical players in the production of evidence.
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